Evidence map›Paper›PMID 42311396›Full record

ArticleFrontiers in veterinary science2026

The therapeutic potential of atorvastatin in treatment of

Khalil Mohamed, Marawan Khodary, Dina Hamed, Abdullah Alhazmi, Hattan S Gattan, Mohammed H Alruhaili, Eman Fathi Fadel, Hatem A Elshabrawy, Asmaa M El-Kady

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Khalil MohamedDepartment of Epidemiology and Medical Statistics, Faculty of Public Health and Health Informatics, Umm Al-Qura University, Mecca, Saudi Arabia.
Marawan KhodaryFaculty of Medicine, Qena University, Qena, Egypt.
Dina HamedDepartment of Medical Parasitology, Faculty of Medicine, Qena University, Qena, Egypt.
Abdullah AlhazmiDepartment of Epidemiology and Medical Statistics, Faculty of Public Health and Health Informatics, Umm Al-Qura University, Mecca, Saudi Arabia.
Hattan S GattanDepartment of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Mohammed H AlruhailiSpecial Infectious Agents Unit, King Fahad Medical Research Center, King AbdulAziz University, Jeddah, Saudi Arabia.
Eman Fathi FadelDepartment of Medical Parasitology, Faculty of Medicine, Sohag University, Sohag, Egypt.
Hatem A ElshabrawyDepartment of Molecular and Cellular Biology, College of Osteopathic Medicine, Sam Houston State University, Conroe, TX, United States.
Asmaa M El-KadyDepartment of Medical Parasitology, Faculty of Medicine, Qena University, Qena, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: Molecular docking simulations were performed to assess the binding affinity of Atorvastatin and MTZ against four key enzymes in the Results: Molecular docking revealed that Atorvastatin exhibited comparable or slightly superior binding affinities to the targeted Conclusion: Atorvastatin possesses a dual therapeutic role against giardiasis. It acts as a moderate antiparasitic agent, likely by targeting the mevalonate pathway, and as a potent immunomodulatory agent. Its superior ability to suppress the inflammatory response and mitigate intestinal and hepatic pathology suggests that Atorvastatin is a promising candidate for an adjunct therapy to Metronidazole, particularly in cases where inflammation and chronic sequelae are major concerns.

Indexed as

giardiasisin silicoin vivometronidazolestatins

Identifiers

PMID42311396
PMCPMC13268923

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.